Deutsche Bank last night initiated coverage of Apogee Therapeutics (APGE) with a Buy rating and $103 price target The firm believes the company could become a leader in atopic dermatitis and asthma with its extended half-life antibodies and fixed-dose combo therapies. While the shares appreciated materially in late 2025, Apogee offers a favorable risk/reward and potential for significant upside ahead of a “catalyst-rich” 2026 with four key readouts, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Apogee Therapeutics initiated with a Buy at Deutsche Bank
- Buy Rating for Apogee Therapeutics: Strong Financials and Promising Pipeline Drive Positive Outlook
- Apogee Therapeutics Reports Q3 2025 Financial Progress
- Positive Buy Rating for Apogee Therapeutics Driven by Promising Clinical Trials and Strategic Advancements
- Apogee Therapeutics Announces Positive Phase 1 Results